Umbilical cord blood transplantation: Current practice and future innovations

Juliet N. Barker, John E. Wagner

Research output: Contribution to journalReview articlepeer-review

71 Scopus citations


As a source of hematopoietic stem cells (HSCs), umbilical cord blood (UCB) has the advantages of speed of availability, tolerance of 1-2 antigen HLA mismatch, and a low incidence of severe GVHD. Thus, UCB represents a highly convenient HSC source that may significantly extend the HSC donor pool. UCB transplantation (UCBT) has become a standard practice in the treatment of pediatric malignancies. Now, UCBT is being investigated in adults using both conventional and non-myeloablative preparative regimens. As graft cell dose is the major factor determining hematopoietic recovery and survival in URD UCBT, methods to increase cell dose such as multiple-unit transplant and ex vivo expansion are being pursued. This review outlines the current status of UCBT with emphasis on current and future innovations.

Original languageEnglish (US)
Pages (from-to)35-43
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Issue number1
StatePublished - Oct 2003

Bibliographical note

Funding Information:
Supported by grants from the National Institute of Health (NOI HB 67139; POI CA 65493, JEW) and Children's Cancer Research Fund (JEW, JNB).

Copyright 2017 Elsevier B.V., All rights reserved.


  • Acute leukemia
  • Allogeneic transplantation
  • Hematopoietic stem cells
  • Umbilical cord blood


Dive into the research topics of 'Umbilical cord blood transplantation: Current practice and future innovations'. Together they form a unique fingerprint.

Cite this